UNA S RYAN
CIK 1255349 · President & CEO · last filed 2026-06-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$93.1K
Companies
5
Total Filings
39
Lifetime Open-Market Net
$49.4K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RNXT | Director | 80,959 | $1.15 | $93.1K | $0 | 7 | 2026-06-24 |
| QNCX | Director | — | $32.73 | — | $0 | 3 | 2025-06-06 |
| Quince Therapeutics, Inc. (CRTX) Delisted | Director | 2,875 | $1.95 | $5.6K | $48.9K | 4 | 2022-06-09 |
| ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Director | 51,845 | — | — | $562 | 22 | 2017-05-11 |
| Celldex Therapeutics, Inc. (AVAND) Delisted | President & CEO | — | — | — | $0 | 1 | 2008-03-11 |
Recent Filings · Page 2 of 4
39 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-10-05 | RNXT | Grant (A) | — | $0 | EDGAR |
| 2021-06-17 | Quince Therapeutics, Inc. (CRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-09 | Quince Therapeutics, Inc. (CRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-03-12 | Quince Therapeutics, Inc. (CRTX) Delisted | Buy (P) | +2,875 | $48.9K | EDGAR |
| 2017-05-11 | ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Exer (M) | +5,000 | $72.3K | EDGAR |
| 2017-02-10 | ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Grant (A) | +3,802 | $0 | EDGAR |
| 2016-10-06 | ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Mixed | +1,502 | -$1 | EDGAR |
| 2016-06-16 | ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Grant (A) | +4,048 | $60.0K | EDGAR |
| 2016-02-08 | ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Grant (A) | +2,854 | $45.0K | EDGAR |
| 2015-06-15 | ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Grant (A) | +1,126 | $22.5K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.